Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Income from Continuing Operations (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Income from Continuing Operations readings, the most recent being 1690000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 88.53% to 1690000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 27110000.0, a 51.68% increase, with the full-year FY2025 number at 27110000.0, up 51.68% from a year prior.
  • Income from Continuing Operations hit 1690000.0 in Q4 2025 for Amicus Therapeutics, down from 17306000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 17306000.0 in Q3 2025 to a low of 85260000.0 in Q1 2022.
  • Median Income from Continuing Operations over the past 5 years was 38537500.0 (2023), compared with a mean of 36091400.0.
  • The widest YoY moves for Income from Continuing Operations: up 357.19% in 2025, down 88.53% in 2025.
  • Amicus Therapeutics' Income from Continuing Operations stood at 83277000.0 in 2021, then skyrocketed by 32.92% to 55865000.0 in 2022, then soared by 39.42% to 33843000.0 in 2023, then soared by 143.55% to 14739000.0 in 2024, then crashed by 88.53% to 1690000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 1690000.0 (Q4 2025), 17306000.0 (Q3 2025), and 24420000.0 (Q2 2025) per Business Quant data.